Navigating Comorbidities and Treatment Decisions in Metastatic Castration-Sensitive Prostate Cancer

Welcome back to another Urology Times Virtual Tumor Board series. In this episode titled, “Navigating Comorbidities and Treatment Decisions in Metastatic Castration-Sensitive Prostate Cancer,” expert faculty discuss a patient with advanced prostate cancer whose management highlights the importance of individualized treatment decisions that extend beyond tumor characteristics alone.

The panel reviews the case of a 78-year-old man with low-volume metastatic castration-sensitive prostate cancer (mCSPC), significant cardiovascular comorbidities, diabetes, and multiple concomitant medications. As the discussion unfolds, the expert faculty explore how chronological age, physiological fitness, cardiovascular risk, and patient preferences should influence treatment selection. The conversation emphasizes the importance of balancing treatment intensification with quality-of-life considerations, while also accounting for drug-drug interactions, polypharmacy, and the management of pre-existing comorbidities.

The panel examines the evolving treatment landscape for mCSPC, including the role of androgen deprivation therapy (ADT), androgen receptor pathway inhibitors (ARPIs), and the appropriate use of treatment intensification strategies. Expert faculty discuss the value of advanced imaging with PSMA PET, germline and somatic testing, and the potential role of metastasis-directed therapy in patients with limited metastatic disease. The discussion also highlights findings from the ARANOTE trial and a recent post hoc analysis evaluating outcomes in patients with varying comorbidity burdens. Panelists review efficacy and safety data, with particular attention to cardiovascular considerations and the real-world challenges of treating older patients with multiple health conditions. Throughout the program, the panel underscores a central theme of modern prostate cancer care: optimizing outcomes requires treating the whole patient—not just the cancer.

In the next episode, “Preserving Quality of Life in Metastatic Castration-Sensitive Prostate Cancer,” panelists continue their discussion of treatment selection in patients with metastatic castration-sensitive prostate cancer, with a focus on cognitive function, independence, and quality-of-life priorities. The panel explores how factors such as baseline cognitive impairment, treatment-related cognitive changes, and patient goals can influence ARPI selection, monitoring strategies, and shared decision-making throughout the treatment journey.